GSK241115P37000
- 3.60
- +0.73+25.44%
GlaxoSmithKline Newsroom
GlaxoSmithKline (GSK) Gets a Hold From Goldman Sachs
GSK Analyst Ratings
GSK Target Cut to 1,525p From 2,000p by Jefferies
Jefferies Downgrades GlaxoSmithKline(GSK.US) to Hold Rating, Cuts Target Price to $39.5
GlaxoSmithKline (GSK) Was Downgraded to a Hold Rating at Jefferies
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
GSK Cut to Neutral From Buy by Guggenheim
GSK Analyst Ratings
Guggenheim Downgrades GlaxoSmithKline(GSK.US) to Hold Rating
BofA Securities Maintains GlaxoSmithKline(GSK.US) With Sell Rating
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), GlaxoSmithKline (GSK) and Amylyx Pharmaceuticals Inc (AMLX)
GlaxoSmithKline (GSK) Gets a Sell From J.P. Morgan
Graham Parry Recommends Sell Rating for GlaxoSmithKline Due to Concerns Over Arexvy Vaccine Efficacy and Safety
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GB:GSK), Gritstone Oncology (GRTS) and Immutep (IMMP)
GlaxoSmithKline (GSK) Gets a Hold From Kepler Capital
GlaxoSmithKline (GSK) Receives a Hold From Goldman Sachs
GlaxoSmithKline (GSK) Gets a Hold From Barclays
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GB:GSK), Sonova Holding AG (Six Swiss: CH:SOON) and Corbus Pharmaceuticals (CRBP)